Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Assessment of Safety and Efficacy of a New Intravenous Immunoglobulin (IGIV3I 10% Grifols) In Subjects with Chronic Immune Thrombocytopenia

Blood (2010) 116 (21): 4669.

https://doi.org/10.1182/blood.V116.21.4669.4669

Published: 2010

Journal Articles

Long-Term Safety and Efficacy of Oral Eltrombopag for the Treatment of Subjects with Idiopathic Thrombocytopenic Purpura (ITP): Preliminary Data from the EXTEND Study.

James B. Bussel, MD, Gregory Cheng, MD, Lidia Kovaleva, MD, Mansoor N. Saleh, MD, Balkis Meddeb, MD, Bhabita Mayer, PhD, J. Lee Fraser, PhD, Manuel Aivado, MD

Blood (2007) 110 (11): 566.

https://doi.org/10.1182/blood.V110.11.566.566

Published: 2007

Journal Articles

Study on the Efficacy and Safety of IGIV3I Grifols (Human Intravenous Immunoglobulin) in Patients Diagnosed with Chronic Immune Thrombocytopenic Purpura.

Antonio Julia, MD, PhD, Lidia Kovaleva, MD, PhD, Ignacio Alberca, MD, PhD, Fernando Hernandez, MD, PhD, Svetlana Loria, MD, PhD, Virgilio Sandoval, MD, PhD, Antonio Vidaller, MD, PhD, Jorge Sierra, MD, PhD

Blood (2006) 108 (11): 3956.

https://doi.org/10.1182/blood.V108.11.3956.3956

Published: 2006

Journal Articles

Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor.

James B. Bussel, MD, Gregory Cheng, MD, Mansoor Saleh, MD, Lidia Kovaleva, MD, Nicole Stone, PhD, Bhabita Mayer, MS, Julian Jenkins, MS, Andrew Provan, BSc, MBChB, MD

Blood (2006) 108 (11): 475.

https://doi.org/10.1182/blood.V108.11.475.475

Published: 2006

Journal Articles

An Open Label, Multi Center Study on the Efficacy and Safety of a Liquid, Ready-to-Use Intravenously Administered Anti-D Immunoglobulin in Patients with Chronic Immune Thrombocytopenic Purpura.

Louis M. Aledort, MD, Abdulgabar Salama, MD, Lidia Kovaleva, MD, Tadeusz Robak, MD, Benjamin Brenner, MD, Adrian Newland, MD, Simon Davies, MD, Diane J. Nugent, MD, Alphonse Hubsch, DVM, Irmgard Andresen, MD, Othmar Zenker, MD

Blood (2004) 104 (11): 3943.

https://doi.org/10.1182/blood.V104.11.3943.3943

Published: 2004

NARROW

Assessment of Safety and Efficacy of a New Intravenous Immunoglobulin (IGIV3I 10% Grifols) In Subjects with Chronic Immune Thrombocytopenia

Long-Term Safety and Efficacy of Oral Eltrombopag for the Treatment of Subjects with Idiopathic Thrombocytopenic Purpura (ITP): Preliminary Data from the EXTEND Study.

Study on the Efficacy and Safety of IGIV3I Grifols (Human Intravenous Immunoglobulin) in Patients Diagnosed with Chronic Immune Thrombocytopenic Purpura.

Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor.

An Open Label, Multi Center Study on the Efficacy and Safety of a Liquid, Ready-to-Use Intravenously Administered Anti-D Immunoglobulin in Patients with Chronic Immune Thrombocytopenic Purpura.

Email alerts

ASH Publications

American Society of Hematology

Assessment of Safety and Efficacy of a New Intravenous Immunoglobulin (IGIV3I 10% Grifols) In Subjects with Chronic Immune Thrombocytopenia

Long-Term Safety and Efficacy of Oral Eltrombopag for the Treatment of Subjects with Idiopathic Thrombocytopenic Purpura (ITP): Preliminary Data from the EXTEND Study.

Study on the Efficacy and Safety of IGIV3I Grifols (Human Intravenous Immunoglobulin) in Patients Diagnosed with Chronic Immune Thrombocytopenic Purpura.

Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor.

An Open Label, Multi Center Study on the Efficacy and Safety of a Liquid, Ready-to-Use Intravenously Administered Anti-D Immunoglobulin in Patients with Chronic Immune Thrombocytopenic Purpura.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only